Physician Speaker and Consulting Payments: When the Lecture Is Optional

Physician speaker program kickbacks use speaking fees, meals, travel or other benefits to buy prescriptions that federal health care programs pay for. The invitation calls it education. The sales team may choose the speaker for prescribing volume, keep inviting the same doctors and pay the fee even when nobody delivers the lecture. If you schedule the events, process the payments or work inside the practice, you may know what happened between the invitation and the prescription.

Do Doctors Get Kickbacks From Meds They Prescribe?

Yes, drug and device companies have used speaker programs to pay doctors for prescribing their products. The HHS Office of Inspector General’s speaker-program alert describes cases involving high-prescriber selection, sales targets and lucrative speaking arrangements. In that November 2020 alert, the agency reported nearly $2 billion in speaker-related payments from drug and device companies over the preceding three years.

A company-sponsored speaker program pays a physician or another health professional to present information about a drug, device or disease. The company typically supplies the presentation and pays an honorarium, often also providing meals for attendees. The company is paying both for the presentation and for access to the people who choose its products.

These physician kickback arrangements reach beyond the speaking fee. The Anti-Kickback Statute prohibits offering or paying benefits on purpose to buy federally payable prescriptions or orders. It also covers doctors who deliberately ask for or accept benefits in return for that business.

A 2020 review in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, connects the kickback arrangement to the False Claims Act through the claim for payment. That gives the examination a destination: the prescription that reached Medicare, Medicaid or another federal program. We connect the manufacturer’s spending, the physician’s prescribing and the resulting claims, even when different businesses hold those records.

The Inspector General’s alert also cites studies finding that health professionals receiving company payments were more likely to prescribe or order that company’s products. Its concern reaches the patient’s treatment decision: financial incentives can favor the physician and manufacturer over the patient.

When the Educational Purpose Disappears

The Inspector General’s alert identifies programs whose content, audience, selection and compensation point toward buying prescriptions. A delivered lecture can still be part of an exchange intended to buy prescriptions. The recurring characteristics fit together:

• The presentation: Little or no substantive information is delivered, or the same topic keeps returning despite no meaningful new medical information.
• The audience: Doctors repeatedly attend the same talk, including after giving it themselves. Guests include friends, family or practice staff without a reason to use the information.
• The setting: Entertainment venues, expensive meals and alcohol take over an event supposedly built around learning.
• The selection: Sales or marketing staff influence who speaks or attends, using past prescribing or expected revenue to choose them.
• The compensation: Fees exceed fair market value for the work, or the amount depends on past or expected business from the physician.

The alert also asks why paid events are needed when the information is available through medical journals, product information and other educational resources. That question becomes concrete when the same physician returns to the same presentation and the company keeps paying. The insider can explain whether the program had anything new to teach and what the sales team expected it to produce.

Novartis Paid for Events That Never Happened

Novartis agreed in July 2020 to pay $591,442,008 in federal False Claims Act damages over speaker programs that included paid events that never happened. The Justice Department’s settlement announcement described allegations that the company used sham events to induce prescriptions for cardiovascular and diabetes drugs reimbursed by federal healthcare programs. A whistleblower brought the matter to the government through a False Claims Act complaint.

The government alleged that sales representatives selected high-volume prescribers, pressured them to write more prescriptions and dropped doctors from the program when they failed to do so. Its complaint put the instruction inside the room:

In its settlement, Novartis admitted that some sales representatives intended honoraria to induce more prescribing. It admitted paying doctors for events that never took place and repeatedly buying dinner for the same groups of colleagues or friends, who sometimes rotated as the paid speaker. The company also admitted that at many programs, paid speakers delivered no presentation or clicked through the slides in minutes before everyone returned to dinner.

The paperwork could be as manufactured as the educational purpose. Novartis admitted that a sales representative on Long Island arranged for a restaurant to create fake receipts, then used the event budget to buy gift cards for high-prescribing doctors. Doctors also received speaking fees for those sham events. We see the absurdity in the company’s own admissions: the dinner could disappear, the presentation could disappear, and the payment still arrived. Education, apparently optional.

The signed settlement connects the events to the sales machinery. Novartis admitted using prescribing data to identify high-volume doctors and track their prescriptions over time. Its marketing science group measured the return on speaker programs by the new prescriptions written by attendees. An event log and a prescribing report were different views of the same commercial effort.

Gilead Shows What Repeat Attendance Can Reveal

Gilead’s HIV speaker programs show why the pattern across events matters. In its April 2025 settlement, the company agreed to pay $202 million to resolve allegations that honoraria, meals and travel induced prescriptions and caused false claims to federal health programs. The government joined a case brought by a whistleblower.

Gilead admitted that one speaker received over $300,000 in honoraria and wrote prescriptions for its HIV drugs that resulted in over $6 million in Medicare, Medicaid and TRICARE payments. That one speaker shows the exchange behind the company-wide settlement: the honorarium went to the doctor, while federal programs paid for the drugs. The prescribing records belong beside the event budget.

The company also admitted that over 250 prescribers attended dinner programs on the same topic at least three times within six months. Some doctors attended talks on topics they had recently been paid to teach. Gilead also admitted paying for speakers to travel to destinations such as Hawaii, sometimes at the speaker’s request. Its policies failed to prevent improper honoraria, meals and travel intended to induce prescribing, the company admitted.

For the person coordinating those programs, the repetition has a familiar shape: the same topic, the same names and another payment or meal. The schedule can show a pattern that a single invitation leaves out. The government alleged that Gilead’s own data should have exposed the abuses.

Consulting Fees and Royalties Follow the Same Business Question

A consulting agreement describes work the physician is supposed to perform. The useful comparison is between that work, the compensation and the business the company expected from the physician. The Inspector General’s alert connects consulting and speaking arrangements to the concern that payments influence prescribing or product use.

Biogen agreed to a $900 million settlement in September 2022 over allegations that speaker honoraria, speaker training fees, consulting fees and meals induced prescriptions for its multiple sclerosis drugs. A former employee brought and pursued the whistleblower case, alleging that those payments caused false Medicare and Medicaid claims. The alleged benefits went to physicians, while public programs paid the drug bills.

Royalties can create a more indirect incentive. In a May 2026 advisory opinion concerning orthopedic technology, the Inspector General gave an unfavorable assessment of proposed consulting royalties despite a fair-market-value certification and the exclusion of direct sales. Training and proctoring could generate other sales included in the royalty revenue. For someone administering the consulting agreement, the royalty calculation shows which sales increase the doctor’s pay. We examine that calculation alongside the work delivered and the business the physician could influence by teaching others to use the technology.

How to Find Out If Your Doctor Is Getting Kickbacks From Pharmaceutical Companies?

The Centers for Medicare & Medicaid Services’ Open Payments database identifies reported financial relationships between physicians and drug or device companies. The agency publishes payment information supplied and attested to by the reporting companies. Understanding what a particular relationship bought takes the event records, the work performed and the prescribing decisions behind that disclosure.

For a practice insider, the useful next conversation is about what you saw. Did the speaker deliver the presentation, did the listed attendees come, and did sales staff discuss the prescriptions they expected? We put that knowledge beside the reported payments and the company’s own records. The person who handled the schedule or invoices can explain details that an amount in a database leaves unanswered.

When the Attendance Record Changes the Price of Dinner

Salix admitted a way to make an expensive program appear to meet its policies. In its June 2016 civil settlement, the company admitted that sales representatives reported physicians as attendees even though they had not come, lowering the apparent cost per person. A false attendee changed the expense calculation.

Salix also admitted paying designated speakers who were supposed to answer questions after prerecorded presentations but were never called. In other instances, representatives never played the presentation or placed the device where attendees could barely see or hear it. The company admitted that its monitoring and review of program data were inadequate. Someone processing those events could see a paid speaker, a completed attendance record and an educational session that never reached the room.

What the Company Chose Not to Write Down

We examine how the company responded when its event records and prescribing reports pointed toward buying prescriptions. Internal objections and the company’s response can explain how the pattern continued. Novartis’s admitted compliance training shows where attention went. Its chief compliance officer said in training presentations:

We see advice about leaving a record where an insider would expect a clear instruction to stop buying prescriptions. The same settlement admitted that potential misconduct went uninvestigated because of a backlog. What the company knew, what it chose to record and what it left running belong beside the payments.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Your knowledge of why the event records and the prescribing story diverge gives us something specific to investigate with you.

You Know What Happened at the Program

If you know who chose the speakers, what the events delivered or how the payments followed prescribing, speak with our whistleblower experts about the program you worked on. We work beside you to build the case from the commercial decisions through to the government claims, and bring in healthcare fraud whistleblower lawyers who understand physician payment schemes. You bring the inside knowledge; we bring the judgment and partnership to pursue it with you.